Literature DB >> 32604404

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.

Enrico Lavezzo1, Elisa Franchin1, Constanze Ciavarella2, Gina Cuomo-Dannenburg2, Luisa Barzon1, Claudia Del Vecchio1, Lucia Rossi3, Riccardo Manganelli1, Arianna Loregian1, Nicolò Navarin4,5, Davide Abate1, Manuela Sciro3, Stefano Merigliano6, Ettore De Canale3, Maria Cristina Vanuzzo3, Valeria Besutti3, Francesca Saluzzo1, Francesco Onelia1, Monia Pacenti3, Saverio G Parisi1, Giovanni Carretta3, Daniele Donato3, Luciano Flor3, Silvia Cocchio7, Giulia Masi1, Alessandro Sperduti4,5, Lorenzo Cattarino2, Renato Salvador6, Michele Nicoletti8, Federico Caldart8, Gioele Castelli8, Eleonora Nieddu8, Beatrice Labella8, Ludovico Fava8, Matteo Drigo8, Katy A M Gaythorpe2, Alessandra R Brazzale9, Stefano Toppo1,5, Marta Trevisan1, Vincenzo Baldo7, Christl A Donnelly2,10, Neil M Ferguson2, Ilaria Dorigatti11, Andrea Crisanti12,13.   

Abstract

On 21 February 2020, a resident of the municipality of Vo', a small town near Padua (Italy), died of pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection1. This was the first coronavirus disease 19 (COVID-19)-related death detected in Italy since the detection of SARS-CoV-2 in the Chinese city of Wuhan, Hubei province2. In response, the regional authorities imposed the lockdown of the whole municipality for 14 days3. Here we collected information on the demography, clinical presentation, hospitalization, contact network and the presence of SARS-CoV-2 infection in nasopharyngeal swabs for 85.9% and 71.5% of the population of Vo' at two consecutive time points. From the first survey, which was conducted around the time the town lockdown started, we found a prevalence of infection of 2.6% (95% confidence interval (CI): 2.1-3.3%). From the second survey, which was conducted at the end of the lockdown, we found a prevalence of 1.2% (95% CI: 0.8-1.8%). Notably, 42.5% (95% CI: 31.5-54.6%) of the confirmed SARS-CoV-2 infections detected across the two surveys were asymptomatic (that is, did not have symptoms at the time of swab testing and did not develop symptoms afterwards). The mean serial interval was 7.2 days (95% CI: 5.9-9.6). We found no statistically significant difference in the viral load of symptomatic versus asymptomatic infections (P = 0.62 and 0.74 for E and RdRp genes, respectively, exact Wilcoxon-Mann-Whitney test). This study sheds light on the frequency of asymptomatic SARS-CoV-2 infection, their infectivity (as measured by the viral load) and provides insights into its transmission dynamics and the efficacy of the implemented control measures.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32604404     DOI: 10.1038/s41586-020-2488-1

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  330 in total

1.  Retail store customer flow and COVID-19 transmission.

Authors:  Robert A Shumsky; Laurens Debo; Rebecca M Lebeaux; Quang P Nguyen; Anne G Hoen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

2.  How Iceland hammered COVID with science.

Authors:  Megan Scudellari
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

3.  Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis.

Authors:  Matt Stevenson; Andrew Metry; Michael Messenger
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 4.  Non-pharmaceutical interventions during the COVID-19 pandemic: A review.

Authors:  Nicola Perra
Journal:  Phys Rep       Date:  2021-02-13       Impact factor: 25.600

Review 5.  Unveiling Human Non-Random Genome Editing Mechanisms Activated in Response to Chronic Environmental Changes: I. Where Might These Mechanisms Come from and What Might They Have Led To?

Authors:  Loris Zamai
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

6.  Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy.

Authors:  Valeria Cento; Claudia Alteri; Marco Merli; Federica Di Ruscio; Livia Tartaglione; Roberto Rossotti; Giovanna Travi; Marta Vecchi; Alessandro Raimondi; Alice Nava; Luna Colagrossi; Roberto Fumagalli; Nicola Ughi; Oscar Massimiliano Epis; Diana Fanti; Andrea Beretta; Filippo Galbiati; Francesco Scaglione; Chiara Vismara; Massimo Puoti; Daniela Campisi; Carlo Federico Perno
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

Review 7.  COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection.

Authors:  Kevin Escandón; Angela L Rasmussen; Isaac I Bogoch; Eleanor J Murray; Karina Escandón; Saskia V Popescu; Jason Kindrachuk
Journal:  BMC Infect Dis       Date:  2021-07-27       Impact factor: 3.090

8.  Comparative effects of viral-transport-medium heat inactivation upon downstream SARS-CoV-2 detection in patient samples.

Authors:  Jamie L Thompson; Angela Downie Ruiz Velasco; Alice Cardall; Rebecca Tarbox; Jaineeta Richardson; Gemma Clarke; Michelle Lister; Hannah C Howson-Wells; Vicki M Fleming; Manjinder Khakh; Tim Sloan; Nichola Duckworth; Sarah Walsh; Chris Denning; C Patrick McClure; Andrew V Benest; Claire H Seedhouse
Journal:  J Med Microbiol       Date:  2021-03-18       Impact factor: 2.472

9.  Higher Viral Load Drives Infrequent Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Between Asymptomatic Residence Hall Roommates.

Authors:  Kristen K Bjorkman; Tassa K Saldi; Erika Lasda; Leisha Conners Bauer; Jennifer Kovarik; Patrick K Gonzales; Morgan R Fink; Kimngan L Tat; Cole R Hager; Jack C Davis; Christopher D Ozeroff; Gloria R Brisson; Daniel B Larremore; Leslie A Leinwand; Matthew B McQueen; Roy Parker
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 5.226

10.  Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies.

Authors:  Sean X Naughton; Urdhva Raval; Giulio M Pasinetti
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.